We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+1.61%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$71.7B
AUM Growth
+$2.34B
Cap. Flow
+$1.49B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.97%
Holding
3,809
New
183
Increased
1,708
Reduced
1,572
Closed
206

Sector Composition

Rank Sector Weight
1 Technology 10.59%
2 Financials 9.51%
3 Healthcare 8.04%
4 Industrials 6.62%
5 Communication Services 5.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AIMT
2576
DELISTED
Aimmune Therapeutics
AIMT
$536K ﹤0.01%
25,585
-15,980
-38% -$326K
P
2577
Everpure Inc
P
$35.8B
$535K ﹤0.01%
31,611
-340,127
-91% -$5.33M
QCRH icon
2578
QCR Holdings
QCRH
$1.71B
$535K ﹤0.01%
14,080
JOE icon
2579
St. Joe Company
JOE
$3.88B
$534K ﹤0.01%
31,200
-5,136
-14% -$91.2K
BCSF icon
2580
Bain Capital Specialty
BCSF
$844M
$532K ﹤0.01%
28,573
CSTM icon
2581
Constellium
CSTM
$4.06B
$532K ﹤0.01%
41,877
-2,146
-5% -$25.3K
MED icon
2582
Medifast
MED
$130M
$532K ﹤0.01%
+5,134
New +$552K
RNR icon
2583
RenaissanceRe
RNR
$13.2B
$530K ﹤0.01%
2,738
+1,118
+69% +$208K
NMIH icon
2584
NMI Holdings
NMIH
$3.35B
$529K ﹤0.01%
20,134
-1,038
-5% -$28.4K
WDIV icon
2585
State Street SPDR S&P Global Dividend ETF
WDIV
$279M
$529K ﹤0.01%
7,832
-36
-0.5% -$2.39K
AVTA
2586
DELISTED
Avantax, Inc. Common Stock
AVTA
$526K ﹤0.01%
24,304
+4,900
+25% +$124K
FSB
2587
DELISTED
Franklin Financial Network, Inc.
FSB
$526K ﹤0.01%
17,421
-1,817
-9% -$52.6K
CIT
2588
DELISTED
CIT Group Inc.
CIT
$525K ﹤0.01%
11,582
+5,115
+79% +$238K
CIM
2589
Chimera Investment
CIM
$1B
$523K ﹤0.01%
8,910
+166
+2% +$9.66K
GLAD icon
2590
Gladstone Capital
GLAD
$446M
$523K ﹤0.01%
26,825
-3,738
-12% -$70.6K
CMU
2591
DELISTED
MFS High Yield Municipal Trust
CMU
$522K ﹤0.01%
111,238
-11
-0% -$52
DTH icon
2592
WisdomTree International High Dividend Fund
DTH
$659M
$522K ﹤0.01%
13,387
+1,027
+8% +$40K
JHD
2593
DELISTED
Nuveen High Income December 2019 Target Term Fund
JHD
$519K ﹤0.01%
52,587
-9,232
-15% -$91.2K
BFK
2594
DELISTED
BlackRock Municipal Income Trust
BFK
$518K ﹤0.01%
36,657
-938
-2% -$13.2K
HYT icon
2595
BlackRock Corporate High Yield Fund
HYT
$1.37B
$518K ﹤0.01%
48,219
-14,260
-23% -$152K
EYE icon
2596
National Vision
EYE
$1.78B
$516K ﹤0.01%
21,419
-307
-1% -$8.94K
FTLS icon
2597
First Trust Long/Short Equity ETF
FTLS
$2.49B
$515K ﹤0.01%
12,573
+2,047
+19% +$83.4K
MTG icon
2598
MGIC Investment
MTG
$6.26B
$515K ﹤0.01%
40,910
-2,049
-5% -$26.5K
ZGNX
2599
DELISTED
Zogenix, Inc.
ZGNX
$515K ﹤0.01%
12,855
+1,070
+9% +$49.3K
FICO icon
2600
Fair Isaac
FICO
$22.2B
$514K ﹤0.01%
1,695
-605
-26% -$205K

Similar funds

Raymond James & Associates's Q3 2019 Portfolio in Review

As of Q3 2019, Raymond James & Associates held 3,809 positions worth $71.7B, up 3.4% from $69.4B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Raymond James & Associates's Q3 2019 filing shows 183 new, 1,708 increased, 1,572 reduced and 206 closed positions. Its largest new stake was Change Healthcare Inc. Common Stock: 949,970 shares worth $11.5M. The largest sale was Microchip Technology, an estimated $155M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2019 buy was Change Healthcare Inc. Common Stock: 949,970 shares worth $11.5M.
  • Raymond James & Associates added most to Comcast in Q3 2019, an estimated $203M increase.
  • Raymond James & Associates's biggest Q3 2019 reduction was Microchip Technology, cutting an estimated $155M.
  • Raymond James & Associates fully exited Anadarko Petroleum in Q3 2019, selling an estimated $89.3M.
  • Raymond James & Associates's ten largest holdings make up 22% of its $71.7B portfolio in Q3 2019.
  • Raymond James & Associates opened 183 new positions and closed 206 in Q3 2019.
  • Raymond James & Associates's portfolio value rose 3.4% quarter-over-quarter to $71.7B.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.